CHMP backs Zepzelca plus Tecentriq for first-line ES-SCLC

The European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, has recommended expanding the EU label for Zepzelca (lurbinectedin) in combination with Tecentriq (atezolizumab) as a first-line maintenance treatment for adults with extensive-stage small cell lung cancer, or ES-SCLC, whose disease has not progressed after induction with atezolizumab, carboplatin, and etoposide. The recommendation follows results from the phase 3 IMforte trial, which showed the combination improved both progression-free survival and overall survival versus atezolizumab alone in the maintenance setting. In the trial, median overall survival was 13.2 months with lurbinectedin plus atezolizumab versus 10.6 months with atezolizumab alone, and grade 3-4 adverse events were more common with the combination. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals tracking comparative oncology and the broader oncology drug pipeline, this is another example of maintenance therapy moving earlier in the treatment course for aggressive cancers with limited options. It also highlights how regulators are weighing survival gains against added hematologic and systemic toxicity, a familiar balance in oncology practice across species. The EU recommendation is especially notable because Tecentriq is already established in first-line ES-SCLC in Europe, and this would extend its use into a maintenance combination after induction therapy. (ema.europa.eu)

What to watch: The next step is a formal European Commission decision, which typically follows a positive CHMP opinion, along with country-level reimbursement discussions that will shape real-world uptake. (ema.europa.eu)